Indacaterol

Drug #2324

Indacaterol maleate is a selective beta2-adrenergic agonist. Its chemical name is (R)-5-[2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl]-8- hydroxy-1H-quinolin-2-one maleate.it is indicated for long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to hydroxyquinolones.

It belongs to Beta-2 adrenergic agonist pharmacological group on the basis of mechanism of action.

Molecular Weight: 508.56 · Solubility in Water: very slightly soluble · Solubility in Alcohol: very slightly soluble · Non-proprietary name: Indacaterol.

Pharmacokinetics

Absorption: Indacaterol has an oral bioavailability is 44% (±1%).

Distribution: Indacaterol has a volume of distribution is 2,361 L to 2,557 L. plasma protein binding is 95.1-96.2%,.

Elimination: plasma half-life is 45.5 to 126 hours, renal excretion is fecal more, urinary less.

Indications

Indacaterol is primarily indicated in conditions like Chronic bronchitis, Chronic obstructive pulmonary disease, Emphysema.

Contraindications

None recorded.

Dosage

Indacaterol's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
75 mcg	75 mcg	—	inhalation	capsules must not be swallowed as the intended effects on the lungs will not be obtained
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

22 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Indacaterol is known to cause more or less tolerable side effects which are usually transient. These include Cough , Headache, Nasopharyngitis, Nausea, oropharyngeal pain.

Warnings / Precautions

Do not initiate in acutely deteriorating COPD patients. Do not use for relief of acute symptoms. Concomitant short-acting beta2- agonists can be used as needed for acute relief. Do not exceed the recommended dose. Excessive use or use inconjunction with other medications containing LABA can result in clinically significant cardiovascular effects and may be fatal. Immediate hypersensitivity reactions may occur. Discontinue immediately. Life-threatening paradoxical bronchospasm can occur. Discontinue immediately. Use with caution in patients with cardiovascular or convulsive disorders, thyrotoxicosis or sensitivity to sympathomimetic drugs.

Available Brands

None recorded.

Storage Conditions

Indacaterol should be stored ( indacaterol inhalation powder) Capsule.

Drug Classification

1.25.1.2 — Inhalants